Does CDKN2A loss predict palbociclib benefit?

J. Gao, R.P Adams, S.M. Swain

Abstract


Palbociclib, an oral small-molecule inhibitor of cyclin-dependent kinases 4 and 6, was recently approved by the U.S. Food and Drug Administration in combination with letrozole for postmenopausal women with advanced hormone receptor–positive, her2-negative breast cancer. Patients with loss of CDKN2A (p16), an inherent negative regulator of cyclin-dependent kinases 4 and 6, were not separately studied because of the significant response of the patients selected based only on receptor status. Here, we report a patient with metastatic estrogen receptor– positive, her2-negative breast cancer with CDKN2A loss who experienced a clinical response to palbociclib.


Keywords


Medical oncology; breast cancer

Full Text:

PDF HTML


DOI: http://dx.doi.org/10.3747/co.22.2700






Copyright © 2019 Multimed Inc.
ISSN: 1198-0052 (Print) ISSN: 1718-7729 (Online)